Mundipharma has a portfolio of medicines within diabetes, respiratory, oncology, pain and biosimilars. The k-haler is a breath-triggered inhaler, that automatically releases a dose of medication as the asthma patient breathes in through the mouthpiece. W was asked to support the launch of the k-haler in the Nordics by developing a communication platform campaign to communicate the key benefits of the k-haler to Healthcare Professionals (HCP).
Drawing from our in-depth knowledge within the asthma therapy area, the team at W developed a sales story flow and key selling messages to communicate the key benefits of the k-haler. A complex story with complex lung deposition data was translated to an understandable and compelling flow, targeting respiratory specialists treating asthma patients in a hospital setting.